Cantanhede, Portugal and Dublin, Ireland; 30 September 2024

A Chrysea sponsored randomized clinical study published in Nutrition Research is the first publication of a human study of high-purity (98%) spermidine.

The study (NCT05459961) “Supplementation of Spermidine at 40 mg/day has Minimal Effects on Circulating Polyamines: An Exploratory Double-blind Randomized Controlled Trial in Older Men“  showed that 40mg/day of high purity spermidine supplement for 28 days is safe in healthy men, with surprisingly little effect on circulating polyamine homeostasis, and that human safety is supported by the wide safety margin as previously published in a comprehensive and full pre-clinical toxicology study with pure spermidine.

“Chrysea is pleased to present to the longevity biotech community a pure and natural product produced by sustainable synthetic biology technology, such as Sprevive® and to enable additional research into this exciting area” said Dr. Patrick Keohane, Chief Medical Officer of Chrysea.

Extensive cell studies and pre-clinical models have demonstrated biological benefits from supplementation with spermidine, particularly in cardiovascular function but also immune, gut, microbiome, and metabolic function. To date, clinical studies have been hampered by the lack of a pure spermidine product for human use in a form that enables full-dosing.

For more information, please visit http://www.chrysealabs.com or contact info@chrysealabs.com

About Sprevive®

Sprevive® is the first pure (98%) spermidine product produced by sustainable fermentation processes. Sprevive® is the first clinically tested pure spermidine product, with a preclinical regulatory safety package, and recognized by GRAS self-affirmation status for full dose use (20 mg/day). 

Sprevive® is low-volume, water soluble, neutral taste, gluten, allergen, protein, and contaminant free.

About Spermidine

Spermidine is a natural component of our normal diet, with average normal diet intakes reported to be from 4.8 to 17 mg/day.

Extensive pre-clinical model and cell studies have previously demonstrated biological benefits from supplementation with spermidine, particularly in cardiovascular function but also immune, gastrointestinal function, the microbiome, and metabolic function.  In the past, clinical studies have been hampered by the lack of a pure spermidine product endorsed for human use and in a form that enables full dosing.

Spermidine is a mediator of autophagy. In 2016, the Nobel Prize in Physiology and Medicine was awarded to Yoshinori Ohsumi for his discoveries of the mechanisms of autophagy and confirming its highly conserved role in maintaining cellular function. Autophagic processes diminish as the human body ages, and the positive effects of spermidine on aging are considered to be due to its action as a natural inducer of autophagy, thus maintaining the body’s healthy aging capacity.

About Chrysea

Chrysea is a biotechnology company revolutionizing the healthcare and wellness industry with

precision healthy-lifespan interventions. Leveraging tools of Synthetic Biology and Data Analytics we have unlocked the potential to manufacture products of unparalleled purity at scale, introducing solutions previously inaccessible to industry. Our approach integrates these

advanced tools seamlessly into our operations, enabling us to establish a vertically integrated,

sustainable business model that spans from laboratory research directly to the consumer. Chrysea’s products are backed by rigorous science-backed clinical research, ensuring pure, safe, functional ingredients and brands that consumers can trust. Join the movement towards a healthier future with Chrysea. #healthylifestyle #precisionhealth #wellnessindustry #sprevive #spermidine.